LEVY Health offers clinical decision support software that combines medical guidelines, clinical studies, and lab data to define virtual care pathways for patients. Its platform features dynamic medical history intake, automated lab orders, lab-result interpretation, patient triage across treatment complexity, patient education, and direct virtual care. The software supports 152 diagnoses and delivers treatment recommendations aligned with ASRM, ESHRE, and ACOG standards, aiming to shorten time to accurate diagnosis and treatment from years to weeks. LEVY serves customers including Progyny, Boston IVF, Texas Fertility Center, Fertilidad Integral, and Everie. The company plans to integrate its virtual care pathways with electronic medical record software and to accelerate growth across women’s health and reproductive care, offering solutions for fertility clinics, fertility benefit providers, laboratories, and biopharma companies. In October 2024 the company raised $4.5M in funding to support those plans. LEVY Health has developed the LEVY Fertility Code, a CE-compliant software platform that deciphers female fertility based on clinical guidelines from the EU and the U.S. The product analyses female fertility disorders and provides personalised therapy recommendations to help women and couples understand why they have not been able to conceive. The software went live in Germany at the end of January and aims to bring holistic reproductive medicine into users’ homes. Founders Theresa Vilsmaier, Silvia Hecher and Caroline Mitterdorfer lead the company, with Mitterdorfer serving as CEO. The platform focuses on individualised assessments, looking at each woman’s body and situation to inform care. LEVY positions itself to speed up fertility diagnosis and boost chances of conceiving.

Total raised

$7M

Funding rounds

2

Latest round

Equity

Latest activity

Oct 2024